This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Biotech Stock Mailbag: Catalyst Pharma, Amarin, Star Scientific

Stocks in this article: CPRXAMRNKERXSTSI

BOSTON ( TheStreet) -- The Biotech Stock Mailbag is open for business.

@scramjet asks, "How do you feel about $CPRX?"

Ambivalent. The upcoming phase IIb study of CPP-109 (vigabatrin) in cocaine addiction is an important catalyst for Catalyst Pharmaceutical Partners (CPRX) but guessing the outcome is challenging. Results from the study, even if positive, may be hard to interpret.

I haven't noticed traders glomming onto Catalyst yet as a "run-up" trade into the vigabatrin study results expected between now and November 15. Catalyst has been trading flat in the $1.50-to-$1.60 range since the beginning of the month. The big move in the stock from 50 cents to $1.40 occurred in July after Catalyst set the CPP-109 study results for September -- earlier than expected. When September came and went with no results, Catalyst pushed the date back to the first half of November.

Vigabatrin has been approved for decades as an epilepsy/seizure medicine. The drug works by blocking an enzyme responsible for the breakdown of the neurotransmitter GABA in the brain. This increases GABA levels. In addiction, increased GABA levels dampen the effect of dopamine, the neurotransmitter responsible for the "pleasure and reward" perceptions that comes when someone snorts cocaine. GABA also induces relaxation and sleep, which may reduce addictive cravings.

CPP-109 is Catalyst's formulation of vigabatrin. The phase IIb study enrolled 200 patients undergoing treatment for cocaine addiction. After a short pre-treatment screening period, patients are randomized to receive CPP-109 or placebo in addition to addiction counseling for nine weeks.

The primary endpoint of the study is the proportion of patients in each treatment group who are cocaine abstinent during the last two weeks of treatment. Secondary endpoints include the number of days in which cocaine was used and clean urine screens (both measured during the nine-week treatment phase).

Patients are also being followed for another 15 weeks after treatment with CPP-109 or placebo ends. During this followup period, the study will measure the percentage of patients in each arm who relapse.

This is the second phase II study of CPP-109 in cocaine addiction that Catalyst has conducted. The first study was disastrous: 186 patients were enrolled but only 67% completed the 12 weeks of treatment with either CPP-109 or a placebo. Forty-eight percent of patients completed the full 24 weeks, which included a follow-up phase. During the last two weeks of treatment, 8% of patients in the CPP-109 arm were cocaine free compared to 5% in the placebo arm. Needless to say, the result was not statistically significant.

1 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,827.75 +12.81 0.07%
S&P 500 2,072.83 +5.80 0.28%
NASDAQ 4,787.3170 +29.0650 0.61%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs